SCR new drug registration; $11.81
7:09AM Simcere Pharma has received new drug registration approval for Qiangke, its Recombinant Human TNF Receptor-IgG Fusion Protein for Injection (SCR) 11.51 : Co announces that Shanghai Celgen Bio-Pharmaceutical Co., in which it holds a 35% equity interest, has received new drug registration approval for Qiangke, its Recombinant Human TNF Receptor-IgG Fusion Protein for Injection. Qiangke is primarily used for in-patient treatment of ankylosing spondylitis and holds strong market potential. Shanghai Celgen is currently preparing for the upcoming GMP inspection by the SFDA.